Should hyperthermia be included in the benefit catalogue for oncologic indications?: Commercial interests are presumed behind the editorial of R. Sauer et al.

Strahlentherapie und Onkologie

Volumn 189, Issue 1, 2013, Pages 81-83

  Wild, C ^a  

^a LUDWIG BOLTZMANN INSTITUTE FOR LUNG VASCULAR RESEARCH   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER RADIOTHERAPY; DEVICES; FOOD AND DRUG ADMINISTRATION; HUMAN; HYPERTHERMIA; MEDICAL LITERATURE; NOTE; PATIENT SAFETY; PRACTICE GUIDELINE; TREATMENT INDICATION; UTERINE CERVIX CANCER;

EID: 84871766918     PISSN: 01797158     EISSN: 1439099X     Source Type: Journal    
DOI: 10.1007/s00066-012-0265-2     Document Type: Note

References (20)

1. Sauer R, Creeze H, Hulshof M et al (2012) Concerning the final report "Hyperthermia: a systematic review" of the Ludwig Boltzmann Institute for Health Technology Assessment, Vienna, March 2010. Strahlenther Onkol 188(3):209-215
2. Mathis S, Johansson T (2010) Hyperther-mie. In: Decision Support Document. Ludwig Boltzmann Institut für HTA. http://eprints.hta.lbg. ac.at/883/1/DSD-36.pdf. Accessed 23 July 2012
3. United States Securities and Exchange Commission (2011) Investors information on BSD Medical Corporation. http://www.bsdmedical. com/~bsdmedic/files/fillings/16-BSD-Medical-Form-10-Q-2-28-11.pdf. Accessed 23 July 2012
4. Stomp W (2011) BSD-2000 Hyperthermia System Receives FDA HDE Marketing Approval. Medgad-get, http://medgadget.com/2011/11/bsd-2000-hyperthermia-system- receives-fda-hde-market-ing-approval.html. Accessed 23 July 2012
5. BSD Medical Corporation. BSD-Providers. http://www.e-factoryatwork.com/ teamwork-new/bsd-pro/treatment-providers.html. Accessed 23 July 2012
6. G-BA/Gemeinsamer Bundesausschuss, Hyper-thermie (2005) Zusammenfassender Bericht des Unterausschusses "Ärztliche Behandlung" des Gemeinsamen Bundesausschusses über die Bewertung gemäß § 135 Abs. 1 SGB V der Hyperther-mie (u. a. Ganzkörper-Hyperthermie, Regionale Tiefenhyperthermie, Oberflächen-Hyperther-mie, Hyperthermie in Kombination mit Radia-tio und/oder Chemotherapie). G-BA/Gemeinsam-er Bundesausschuss: Siegburg. http://www.g-ba. de/downloads/40-268-236/2005-06-15- BUB-Hy-perthermie.pdf. Accessed 23 July 2012
7. Issels RD, Lindner LH, Verweij J et al (2010) Neo-adjuvant chemotherapy alone or with regional hyperthermia for localised high-risk soft-tissue sarcoma: a randomised phase 3 multicentre study. Lancet Oncol 11(6):561-570
8. Issels RD, Lindner et al (2007) Regional hyper-thermia (RHT) improves response and survival when combined with systemic chemotherapy in the management of locally advanced, high grade soft tissue sarcomas (STS) of the extremities, the body wall and the abdomen: a phase III randomised pros. J Clin Oncol (ASCO Annual Meeting Proceedings (Post-Meeting Edition). 25(18 S (June 20 Supplement)):10009)
9. Falk MH, Issels RD (2001) Hyperthermia in oncology. Int J Hyperthermia 17(1):1-18
10. Lutgens L, Zee J van der et al (2010) Combined use of hyperthermia and radiation therapy for treating locally advanced cervix carcinoma. Co-chrane Database Syst Rev 3:39
11. NCCN/National Comprehensive Cancer Network (2012) National Clinical Practice Guidelines in Oncology. http://www.nccn.org/professionals/phy-sician- gls/pdf. Accessed 23 July 2012
12. NCI/National Cancer Institute. Hyperthermia in cancer treatment. http://www.cancer.gov/can-certopics/factsheet/Therapy/hyperthermia. Accessed 23 July 2012
13. Booth A, Clarke et al (2011) An international registry of systematic-review protocols. Lancet 377:108-109
14. LBI-HTA (2009) (2. Aufl.) Internes Manual. Abläufe und Methoden. http://eprints.hta.lbg. ac.at/713/3/HTA-Projektbericht-06-(2.Auflage). pdf. Accessed 23 July 2012
15. Colombo R, Salonia A et al (2010) Long-term outcomes of a randomized controlled trial comparing thermochemotherapy with mitomy-cin-C alone as adjuvant treatment for non-muscle-invasive bladder cancer (NMIBC). BJU Int 107(6):912-918
16. Bundesanzeiger (2005) Bekanntmachung [1429 A] eines Beschlusses des Gemeinsamen Bundesausschusses über eine Änderung der Anlage
17. B "Nicht anerkannte Untersuchungs-und Behandlungsmethoden" der Richtlinie zur Bewertung medizinischer Untersuchungs-und Behandlungsmethoden (BUB-Richtlinie), Bundesministerium für Gesundheit und Soziale Sicherung, Editor. BAnz. p. 7485. http://www.g-ba.de/downloads/39-261-199/2005-01-18-BUB- Hyper-thermie.pdf. Accessed 23 July 2012
18. Finanzen.net. BSD Medical Aktie. http://www.finanzen.net/kurse/kurse- histo-risch.asp?pkAktieNr =23438&strBoerse = XETRA&pkZeit =50000. Accessed 23 July 2012
19. IQWIG/Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (2012) Interessenskon-flikte. https://www.iqwig.de/index.924. html. Accessed 23 July 2012
20. Lieb K, Klemperer D, Ludwig WD (2011) Interessenkonflikte in der Medizin, 1st edn., Springer, Heidelberg (vol 8)